Jayne D
Division of Renal Medicine, St George's Hospital Medical School, London, UK.
Curr Opin Nephrol Hypertens. 1999 Sep;8(5):563-7. doi: 10.1097/00041552-199909000-00005.
The immunosuppressive drug mycophenolate mofetil is a potential new treatment for autoimmune renal disease. In addition to its effects in modulating the autoimmune response, mycophenolate mofetil reduces adhesion molecule expression and delays the progression of renal failure. Data from experimental models of glomerulonephritis, especially of lupus nephritis, have demonstrated that mycophenolate mofetil reverses both inflammatory and autoimmune aspects of disease and influences outcome. As yet, clinical experience with mycophenolate mofetil remains anecdotal but provides a strong platform for the scientific evaluation of mycophenolate mofetil as a new therapeutic agent for these conditions in the future.
免疫抑制药物霉酚酸酯是治疗自身免疫性肾病的一种潜在新疗法。除了调节自身免疫反应外,霉酚酸酯还能降低黏附分子的表达并延缓肾衰竭进程。肾小球肾炎尤其是狼疮性肾炎实验模型的数据表明,霉酚酸酯能逆转疾病的炎症和自身免疫方面并影响预后。目前,霉酚酸酯的临床经验仍为个案,但为未来将霉酚酸酯作为这些病症的新治疗药物进行科学评估提供了有力平台。